指南与共识妇科

根据2023年FIGO指南更新对子宫癌重新分期并不统一影响预后:一项机构回顾性队列研究

Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study.
指南 / 共识 · Gynecol Oncol · 2024-07-14

本研究回顾性分析2013年9月至2023年5月本机构收治的子宫内膜癌患者并联合TCGA Nature 2013公开数据集,按2023年FIGO指南重新分期。共纳入919例患者,其中机构数据集175例(31.5%)、TCGA数据集115例(31.6%)发生分期改变,绝大多数为分期升高(275/290;94.8%)。原IA期且分期升高的患者3年无进展生存率低于无分期改变者(72.0% vs 92.3%,P=0.002),其他分期亚组未见显著生存差异。

要点

  • 2023年FIGO分期纳入组织学亚型和分子分型后,约三成患者发生分期改变,多为分期升高。
  • 原IA期患者中,分期升高者3年PFS为72.0%,无分期改变者为92.3%,差异显著(P=0.002)。
  • 重新分期至II期或III期亚组的患者未见显著生存差异。

核心结论

  • 原IA期子宫内膜癌患者中,重新分期升高者存在一定生存差异;重新分期至II期或III期亚组者未见显著生存差异,需改进风险评估以指导预后判断和辅助治疗。

研究设计与样本

  • 回顾性队列研究,纳入2013年9月至2023年5月本机构收治的子宫内膜癌患者,并联合TCGA Nature 2013公开数据集,共919例,按2023年FIGO指南重新分期,采用Kaplan-Meier法估计生存并用log-rank检验比较无进展生存曲线。

主要发现

  • 机构数据集175例(31.5%)和TCGA数据集115例(31.6%)发生分期改变,其中275/290例(94.8%)为分期升高。
  • 原IA期无分期改变者3年PFS为92.3%(95% CI:87.2,95.4),分期升高者为72.0%(95% CI:68.4,84.9),P=0.002。
  • 其他分期亚组未见显著生存差异。

关键数值与推荐

  • 2023年FIGO分期纳入组织学亚型和分子分型确定子宫内膜癌分期。
  • 原IA期无分期改变者3年PFS 92.3%(95% CI:87.2,95.4) vs 分期升高者72.0%(95% CI:68.4,84.9),P=0.002。
  • 275/290例(94.8%)分期改变为分期升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Efforts have been made to better risk stratify patients given the rise in incidence of endometrial cancer (EC). The 2023 FIGO staging now incorporates histologic subtype and molecular classification into determination of EC stage. We sought to elucidate if the new staging system demonstrated prognostic differences compared to the 2009 staging system. METHODS: A retrospective chart review was performed on women treated for EC at our institution from September 2013 to May 2023 and combined with the publicly available TCGA Nature 2013 dataset. Detailed clinical information was captured. Patients were restaged according to the 2023 guidelines. Survival estimates were obtained using Kaplan-Meier method, and the log-rank test was used to compare survival curves for progression-free survival (PFS). RESULTS: 919 patients were included in our analysis. The datasets were comparable regarding histologic grade, stage, and age at diagnosis. 175 (31.5%) of patients in the institution dataset and 115 (31.6%) patients in the TCGA dataset experienced a stage change. Most patients whose stage changed were upstaged (275/290; 94.8%). 3-year PFS estimates for stage IA patients with no stage change versus those upstaged were 92.3% (95% CI: 87.2, 95.4) v. 72.0% (95% CI: 68.4, 84.9), p = 0.002. No significant differences in survival difference were seen in other stage subsets. CONCLUSION: Modest survival differences exist in patients with EC originally staged as IA who underwent upstaging. No significant survival difference is observed in patients who are restaged to stage II or III subsets. Improved risk stratification is needed in assessing prognosis and adjuvant therapy for patients with endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Senguttuvan RN, Lugo-Santiago N, Nakamura B, et al. Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study. Gynecol Oncol. 2024. PMID: 39003960. doi:10.1016/j.ygyno.2024.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。